NO328824B1 - Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert. - Google Patents

Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert. Download PDF

Info

Publication number: NO328824B1
Authority: NO; Norway
Prior art keywords: protein; tat; nef; hiv; derivative
Prior art date: 1997-09-26

Application number

NO20001508A

Other languages

English (en)

Norwegian (no)

Other versions

NO20001508D0 (no

NO20001508L (no

Inventor

Claudine Elvire Marie Bruck

Stephane Andre Georges Godart

Martine Marchand

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-26

Filing date

2000-03-23

Publication date

2010-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328824(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-03-23 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2000-03-23 Publication of NO20001508D0 publication Critical patent/NO20001508D0/no

2000-05-18 Publication of NO20001508L publication Critical patent/NO20001508L/no

2010-05-25 Publication of NO328824B1 publication Critical patent/NO328824B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims description 89
102000004169 proteins and genes Human genes 0.000 title claims description 81
239000000203 mixture Substances 0.000 title claims description 29
229960005486 vaccine Drugs 0.000 title claims description 21
238000000034 method Methods 0.000 title claims description 20
108020004707 nucleic acids Proteins 0.000 title claims description 9
102000039446 nucleic acids Human genes 0.000 title claims description 9
150000007523 nucleic acids Chemical class 0.000 title claims description 9
108020001507 fusion proteins Proteins 0.000 title description 22
102000037865 fusion proteins Human genes 0.000 title description 17
238000002360 preparation method Methods 0.000 title description 5
108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 title description 4
108091005461 Nucleic proteins Proteins 0.000 title 1
150000001413 amino acids Chemical class 0.000 claims description 51
101710149951 Protein Tat Proteins 0.000 claims description 50
230000004927 fusion Effects 0.000 claims description 25
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 21
239000002671 adjuvant Substances 0.000 claims description 16
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 14
241000235058 Komagataella pastoris Species 0.000 claims description 13
238000007792 addition Methods 0.000 claims description 12
238000006467 substitution reaction Methods 0.000 claims description 12
210000004899 c-terminal region Anatomy 0.000 claims description 11
238000012217 deletion Methods 0.000 claims description 11
230000037430 deletion Effects 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
241000588724 Escherichia coli Species 0.000 claims description 10
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 9
101710188053 Protein D Proteins 0.000 claims description 9
101710132893 Resolvase Proteins 0.000 claims description 9
108090001030 Lipoproteins Proteins 0.000 claims description 8
102000004895 Lipoproteins Human genes 0.000 claims description 8
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 claims description 7
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 6
108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 5
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 5
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 5
230000001939 inductive effect Effects 0.000 claims description 5
239000007764 o/w emulsion Substances 0.000 claims description 5
229940031439 squalene Drugs 0.000 claims description 5
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 5
229930003799 tocopherol Natural products 0.000 claims description 5
239000011732 tocopherol Substances 0.000 claims description 5
235000010384 tocopherol Nutrition 0.000 claims description 5
229960001295 tocopherol Drugs 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 4
229930182490 saponin Natural products 0.000 claims description 4
150000007949 saponins Chemical class 0.000 claims description 4
241000606768 Haemophilus influenzae Species 0.000 claims description 3
229920000136 polysorbate Polymers 0.000 claims description 3
239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
235000017709 saponins Nutrition 0.000 claims 2
229940047650 haemophilus influenzae Drugs 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 64
235000001014 amino acid Nutrition 0.000 description 42
210000004027 cell Anatomy 0.000 description 35
239000013612 plasmid Substances 0.000 description 24
108020004414 DNA Proteins 0.000 description 21
239000012634 fragment Substances 0.000 description 20
239000013598 vector Substances 0.000 description 20
238000010367 cloning Methods 0.000 description 18
238000010276 construction Methods 0.000 description 17
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
235000014304 histidine Nutrition 0.000 description 13
101710192141 Protein Nef Proteins 0.000 description 11
238000002474 experimental method Methods 0.000 description 9
239000013604 expression vector Substances 0.000 description 9
239000000427 antigen Substances 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
239000000839 emulsion Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 8
230000009466 transformation Effects 0.000 description 8
239000004471 Glycine Substances 0.000 description 7
241000725303 Human immunodeficiency virus Species 0.000 description 7
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 7
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
239000004473 Threonine Substances 0.000 description 7
102000053602 DNA Human genes 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
239000011543 agarose gel Substances 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
239000013613 expression plasmid Substances 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
229930182817 methionine Natural products 0.000 description 5
239000003921 oil Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
108020004705 Codon Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
108700004028 nef Genes Proteins 0.000 description 4
101150023385 nef gene Proteins 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
108700004027 tat Genes Proteins 0.000 description 4
101150098170 tat gene Proteins 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
101710172711 Structural protein Proteins 0.000 description 3
229960000074 biopharmaceutical Drugs 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000001131 transforming effect Effects 0.000 description 3
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
108010025188 Alcohol oxidase Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
235000021360 Myristic acid Nutrition 0.000 description 2
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
241000235648 Pichia Species 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
238000006872 enzymatic polymerization reaction Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000002243 precursor Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
229950003937 tolonium Drugs 0.000 description 2
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000012795 verification Methods 0.000 description 2
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
101150061183 AOX1 gene Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
239000011627 DL-alpha-tocopherol Substances 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
101710204610 Envelope glycoprotein gp160 Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
101150069554 HIS4 gene Proteins 0.000 description 1
108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
-1 MnCh Chemical compound 0.000 description 1
241001092142 Molina Species 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101100525628 Picea mariana SB62 gene Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
229940037003 alum Drugs 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000037798 influenza B Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001589 lymphoproliferative effect Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000004064 recycling Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Virology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO20001508A 1997-09-26 2000-03-23 Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert. NO328824B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9720585.0A GB9720585D0 (en)	1997-09-26	1997-09-26	Vaccine
PCT/EP1998/006040 WO1999016884A1 (en)	1997-09-26	1998-09-17	Fusion proteins comprising hiv-1 tat and/or nef proteins

Publications (3)

Publication Number	Publication Date
NO20001508D0 NO20001508D0 (no)	2000-03-23
NO20001508L NO20001508L (no)	2000-05-18
NO328824B1 true NO328824B1 (no)	2010-05-25

Family

ID=10819735

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20001508A NO328824B1 (no)	1997-09-26	2000-03-23	Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert.
NO20076467A NO20076467L (no)	1997-09-26	2007-12-14	Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20076467A NO20076467L (no)	1997-09-26	2007-12-14	Fusjonsproteiner som omfatter HIV-1 Tat- og/eller Nef-proteiner

Country Status (28)

Country	Link
EP (1)	EP1015596B2 (pt)
JP (2)	JP2001518300A (pt)
KR (1)	KR100554487B1 (pt)
CN (1)	CN1188519C (pt)
AR (2)	AR017147A1 (pt)
AT (1)	ATE338128T1 (pt)
AU (1)	AU746564B2 (pt)
BR (1)	BR9812547A (pt)
CA (1)	CA2305013C (pt)
CO (1)	CO4810339A1 (pt)
CZ (1)	CZ302878B6 (pt)
DE (1)	DE69835756T3 (pt)
DK (1)	DK1015596T4 (pt)
ES (1)	ES2272012T5 (pt)
GB (1)	GB9720585D0 (pt)
HK (1)	HK1030431A1 (pt)
HU (1)	HUP0004896A3 (pt)
IL (1)	IL135102A0 (pt)
NO (2)	NO328824B1 (pt)
NZ (1)	NZ503482A (pt)
PL (1)	PL195243B1 (pt)
PT (1)	PT1015596E (pt)
SA (1)	SA98190877B1 (pt)
SI (1)	SI1015596T2 (pt)
TR (1)	TR200000864T2 (pt)
TW (1)	TW499436B (pt)
WO (1)	WO1999016884A1 (pt)
ZA (1)	ZA988789B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9706957D0 (en)	1997-04-05	1997-05-21	Smithkline Beecham Plc	Formulation
GB9720585D0 (en) *	1997-09-26	1997-11-26	Smithkline Beecham Biolog	Vaccine
GB9820525D0 (en)	1998-09-21	1998-11-11	Allergy Therapeutics Ltd	Formulation
WO2000050077A1 (en) *	1999-02-25	2000-08-31	Smithkline Beecham Biologicals S.A.	Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
ATE342275T1 (de) *	1999-04-12	2006-11-15	Heart Biosystems Gmbh	Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
WO2001000232A2 (en) *	1999-06-29	2001-01-04	Smithkline Beecham Biologicals S.A.	Use of cpg as an adjuvant for hiv vaccine
GB0000891D0 (en)	2000-01-14	2000-03-08	Allergy Therapeutics Ltd	Formulation
EA200200724A1 (ru) *	2000-01-31	2003-02-27	Смитклайн Бичем Байолоджикалз С.А.	Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
WO2006033665A1 (en)	2004-03-16	2006-03-30	Inist Inc.	Tat-based vaccine compositions and methods of making and using same
US6472176B2 (en)	2000-12-14	2002-10-29	Genvec, Inc.	Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) *	2001-04-27	2001-06-20	Glaxosmithkline Biolog Sa	Novel compounds
EP1279404A1 (en) *	2001-07-26	2003-01-29	Istituto Superiore di Sanità	Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) *	2001-07-27	2001-09-19	Glaxosmithkline Biolog Sa	Novel use
EP1944043A1 (en)	2001-11-21	2008-07-16	The Trustees of the University of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
NZ564586A (en)	2001-11-21	2009-09-25	Univ Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) *	2002-01-08	2005-01-14	주식회사 엘지생명과학	인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206359D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
SI1652857T1 (sl)	2002-05-16	2009-02-28	Bavarian Nordic As	Fuzijski protein regulatornih/pomoĹľnih HIV proteinov
GB0225788D0 (en)	2002-11-05	2002-12-11	Glaxo Group Ltd	Vaccine
TW200613554A (en)	2004-06-17	2006-05-01	Wyeth Corp	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
GB0507003D0 (en) *	2005-04-06	2005-05-11	Molmed Spa	Therapeutic
IL286053B2 (en) *	2005-10-18	2023-03-01	Nat Jewish Health	A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
AU2008331906B2 (en)	2007-11-28	2014-03-06	The Trustees Of The University Of Pennsylvania	Simian E adenovirus SAdV-39
EP2463362B1 (en)	2007-11-28	2017-11-08	The Trustees Of The University Of Pennsylvania	Simian subfamily c adenovirus SAdv-31 and uses thereof
CA2716928C (en)	2008-03-04	2018-04-10	The Trustees Of The University Of Pennsylvania	Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
AU2009246876B2 (en)	2008-05-16	2015-04-02	Htyr Acquisition Llc	Antibodies and processes for preparing the same
US9169462B2 (en)	2008-07-21	2015-10-27	Taiga Biotechnologies, Inc.	Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
EP3916010A1 (en)	2008-08-28	2021-12-01	Taiga Biotechnologies, Inc.	Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
WO2010051367A1 (en)	2008-10-31	2010-05-06	The Trustees Of The University Of Pennsylvania	Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof
CN102405057B (zh)	2009-03-23	2016-05-25	那尼尔科斯治疗公司	用免疫刺激性Hiv Tat衍生物多肽治疗癌症
EP2435559A1 (en)	2009-05-29	2012-04-04	The Trustees Of The University Of Pennsylvania	Simian adenovirus 41 and uses thereof
WO2012071318A2 (en)	2010-11-23	2012-05-31	The Trustees Of The University Of Pennsylvania	Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
US9110059B2 (en) *	2011-03-15	2015-08-18	Industry-Academic Cooperation Foundation, Yonsei University	Bio-pin
MX358019B (es)	2012-05-18	2018-08-02	Univ Pennsylvania	Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
WO2014012090A1 (en)	2012-07-13	2014-01-16	The Broad Institute, Inc.	Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
CN114645015A (zh)	2012-07-20	2022-06-21	泰加生物工艺学公司	造血区室的增强的重建和自动重建
US9365825B2 (en)	2013-03-11	2016-06-14	Taiga Biotechnologies, Inc.	Expansion of adult stem cells in vitro
US10272115B2 (en)	2013-03-11	2019-04-30	Taiga Biotechnologies, Inc.	Production and use of red blood cells
RU2695653C2 (ru)	2013-10-04	2019-07-25	Пин Фарма, Инк.	Иммуностимулирующие полипептидные производные тат вич для применения в лечении рака
EP3142750B1 (en)	2014-05-13	2020-07-01	The Trustees Of The University Of Pennsylvania	Compositions comprising aav expressing dual antibody constructs and uses thereof
ES2865392T7 (es) *	2015-04-16	2022-09-07	The Research Foundation For The State Univ Of New York Univ At Buffalo	Nanoestructuras que comprenden conjugados de porfirina de cobalto-fosfolípido y etiquetas de polihistidina
US11207421B2 (en)	2015-04-16	2021-12-28	The Research Foundation For The State University Of New York	Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
CN113786476A (zh)	2016-12-02	2021-12-14	泰加生物工艺学公司	纳米颗粒调配物
US10149898B2 (en)	2017-08-03	2018-12-11	Taiga Biotechnologies, Inc.	Methods and compositions for the treatment of melanoma
US20240226324A1 (en)	2021-04-27	2024-07-11	Generation Bio Co.	Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en)	2022-03-14	2023-09-21	Generation Bio Co.	Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9003010D0 (en) *	1990-02-09	1990-04-04	Glaxo Group Ltd	Gene expression in yeast cells
CA2121493A1 (en) *	1991-10-21	1993-04-29	Charles K. Stover	Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
DE656950T1 (de) *	1992-08-21	1996-03-14	Biogen Inc	Tat-derivate transport polypeptide.
AU675702B2 (en) *	1993-01-26	1997-02-13	Leslie R. Coney	Compositions and methods for delivery of genetic material
CA2215483C (fr) *	1995-03-08	2012-01-03	Jean-Francois Zagury	Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
GB9720585D0 (en) *	1997-09-26	1997-11-26	Smithkline Beecham Biolog	Vaccine

1997
- 1997-09-26 GB GBGB9720585.0A patent/GB9720585D0/en not_active Ceased
1998
- 1998-09-17 EP EP98952625A patent/EP1015596B2/en not_active Expired - Lifetime
- 1998-09-17 PL PL98339432A patent/PL195243B1/pl not_active IP Right Cessation
- 1998-09-17 KR KR1020007003180A patent/KR100554487B1/ko not_active IP Right Cessation
- 1998-09-17 WO PCT/EP1998/006040 patent/WO1999016884A1/en active IP Right Grant
- 1998-09-17 SI SI9830860T patent/SI1015596T2/sl unknown
- 1998-09-17 AT AT98952625T patent/ATE338128T1/de active
- 1998-09-17 CZ CZ20001091A patent/CZ302878B6/cs not_active IP Right Cessation
- 1998-09-17 PT PT98952625T patent/PT1015596E/pt unknown
- 1998-09-17 HU HU0004896A patent/HUP0004896A3/hu unknown
- 1998-09-17 TR TR2000/00864T patent/TR200000864T2/xx unknown
- 1998-09-17 JP JP2000513953A patent/JP2001518300A/ja not_active Withdrawn
- 1998-09-17 IL IL13510298A patent/IL135102A0/xx not_active IP Right Cessation
- 1998-09-17 CN CNB988114321A patent/CN1188519C/zh not_active Expired - Fee Related
- 1998-09-17 BR BR9812547-8A patent/BR9812547A/pt not_active IP Right Cessation
- 1998-09-17 DE DE69835756T patent/DE69835756T3/de not_active Expired - Lifetime
- 1998-09-17 ES ES98952625T patent/ES2272012T5/es not_active Expired - Lifetime
- 1998-09-17 AU AU10255/99A patent/AU746564B2/en not_active Ceased
- 1998-09-17 NZ NZ503482A patent/NZ503482A/en not_active IP Right Cessation
- 1998-09-17 DK DK98952625.6T patent/DK1015596T4/da active
- 1998-09-17 CA CA002305013A patent/CA2305013C/en not_active Expired - Fee Related
- 1998-09-24 AR ARP980104779A patent/AR017147A1/es active IP Right Grant
- 1998-09-25 CO CO98056054A patent/CO4810339A1/es unknown
- 1998-09-25 ZA ZA9808789A patent/ZA988789B/xx unknown
- 1998-10-22 TW TW087117493A patent/TW499436B/zh not_active IP Right Cessation
- 1998-12-15 SA SA98190877A patent/SA98190877B1/ar unknown
2000
- 2000-03-23 NO NO20001508A patent/NO328824B1/no not_active IP Right Cessation
- 2000-12-27 HK HK00108429A patent/HK1030431A1/xx not_active IP Right Cessation
2007
- 2007-12-14 NO NO20076467A patent/NO20076467L/no unknown
2009
- 2009-06-30 JP JP2009155916A patent/JP2009213492A/ja active Pending
2011
- 2011-02-28 AR ARP110100606A patent/AR080331A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1188519C (zh)	2005-02-09
IL135102A0 (en)	2001-05-20
SA98190877B1 (ar)	2006-09-10
AR080331A2 (es)	2012-03-28
NO20001508D0 (no)	2000-03-23
PT1015596E (pt)	2006-12-29
DE69835756T2 (de)	2007-09-13
CN1279718A (zh)	2001-01-10
TW499436B (en)	2002-08-21
ES2272012T5 (es)	2010-07-06
ES2272012T3 (es)	2007-04-16
ATE338128T1 (de)	2006-09-15
CZ20001091A3 (cs)	2000-09-13
NO20001508L (no)	2000-05-18
AU1025599A (en)	1999-04-23
HK1030431A1 (en)	2001-05-04
DK1015596T4 (da)	2010-07-12
JP2001518300A (ja)	2001-10-16
WO1999016884A1 (en)	1999-04-08
GB9720585D0 (en)	1997-11-26
CO4810339A1 (es)	1999-06-30
DK1015596T3 (da)	2007-01-02
PL339432A1 (en)	2000-12-18
EP1015596B2 (en)	2010-04-14
SI1015596T1 (sl)	2007-02-28
DE69835756T3 (de)	2010-09-30
AR017147A1 (es)	2001-08-22
TR200000864T2 (tr)	2000-08-21
KR20010024287A (ko)	2001-03-26
CA2305013C (en)	2008-04-08
CA2305013A1 (en)	1999-04-08
NO20076467L (no)	2000-05-18
HUP0004896A3 (en)	2003-05-28
SI1015596T2 (sl)	2010-07-30
BR9812547A (pt)	2000-07-25
HUP0004896A1 (hu)	2001-04-28
KR100554487B1 (ko)	2006-03-03
ZA988789B (en)	2000-03-29
CZ302878B6 (cs)	2012-01-04
AU746564B2 (en)	2002-05-02
EP1015596B1 (en)	2006-08-30
NZ503482A (en)	2001-09-28
PL195243B1 (pl)	2007-08-31
JP2009213492A (ja)	2009-09-24
DE69835756D1 (de)	2006-10-12
EP1015596A1 (en)	2000-07-05

Legal Events

Date	Code	Title	Description
2015-04-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO328824B1 (no)	2010-05-25	Vaksinesammensetninger som omfatter fusjonsproteiner av HIV-1 NEF-proteiner, fremgangsmate for fremstilling av vaksinesammensetning og protein samt nukleinsyre, proteiner og vert.
KR101501495B1 (ko)	2015-03-11	Ｈｉｖ-감염의 예방 및 치료를 위한 백신
JP2003529559A (ja)	2003-10-07	新規用途
SG184188A1 (en)	2012-10-30	Hiv vaccine
KR20100109555A (ko)	2010-10-08	백신
US20100215681A1 (en)	2010-08-26	Fusion proteins comprising hiv-1 tat and/or nef proteins
MXPA00002973A (en)	2001-05-17	Fusion proteins comprising hiv-1 tat and/or nef proteins